menu
    • menu
    [{"orgOrder":0,"company":"Predictive Oncology","sponsor":"zPREDICTA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Predictive Oncology \/ Predictive Oncology","highestDevelopmentStatusID":"4","companyTruncated":"Predictive Oncology \/ Predictive Oncology"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Cancer Research Horizons","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Predictive Oncology \/ Cancer Research Horizons","highestDevelopmentStatusID":"4","companyTruncated":"Predictive Oncology \/ Cancer Research Horizons"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Private Placement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Predictive Oncology \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Predictive Oncology \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Cvergenx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Predictive Oncology \/ Cvergenx","highestDevelopmentStatusID":"4","companyTruncated":"Predictive Oncology \/ Cvergenx"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Integra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Predictive Oncology \/ Integra Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Predictive Oncology \/ Integra Therapeutics"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Quantitative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Predictive Oncology \/ Predictive Oncology","highestDevelopmentStatusID":"2","companyTruncated":"Predictive Oncology \/ Predictive Oncology"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Dr. Daniel Carter","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"NSP-10 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Predictive Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Predictive Oncology \/ Dr. Daniel Carter","highestDevelopmentStatusID":"6","companyTruncated":"Predictive Oncology \/ Dr. Daniel Carter"},{"orgOrder":0,"company":"Predictive Oncology","sponsor":"Yorkville Advisors Global","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Predictive Oncology","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Predictive Oncology \/ Yorkville Advisors Global","highestDevelopmentStatusID":"4","companyTruncated":"Predictive Oncology \/ Yorkville Advisors Global"}]

    Find Clinical Drug Pipeline Developments & Deals by Predictive Oncology

    Menu

    Predictive Oncology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Yorkville Advisors Global

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville

                            Details : The financing aims to help the Predictive oncology to progress its ongoing drug discovery, biomarker discovery and drug repurposing initiatives.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 08, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Yorkville Advisors Global

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Integra Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy

                            Details : The collaboration is created to pursue a novel method to enhance Integra's ability to use gene editing for future cancer therapies. Predictive Oncology has protein expression experience and unique ability to optimize solubility and physical stability for...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 30, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Integra Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Cancer Research Horizons

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Predictive Oncology And Cancer Research Horizons Have Partnered To Pursue Development Of Cancer Drugs

                            Details : The collaboration utilizes Predictive Oncology’s PEDAL technology to evaluate Cancer Research Horizons’ pre-clinical drug inhibitors of Glutaminase in order to determine which cancer types and patient populations are most likely to respond to treatme...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 17, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Cancer Research Horizons

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Cvergenx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Predictive Oncology and Cvergenx Announce Partnership To Develop The First-ever Genomics-based Approach To Pre...

                            Details : By applying Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities, and the Cvergenx precision genomics radiation therapy platform (pGRT™), the two companies will pursue ways in which to optimize genomically-g...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 23, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Cvergenx

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $17.6 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Predictive Oncology Announces Closing of $17.6 Million Private Placement Priced At-the-Market

                            Details : The Company intends to use up to approximately $5.88 million of the net proceeds to repay certain indebtedness and the remainder of the net proceeds for general corporate purposes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 23, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : H.C. Wainwright & Co

                            Deal Size : $17.6 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : zPREDICTA

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Predictive Oncology Acquires zPREDICTA, Inc

                            Details : The acquisition immediately adds a new anticipated revenue stream to Predictive Oncology and contributes to the company’s larger mission of supporting the development of new cancer therapies from drug discovery through regulatory approval.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 12, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : zPREDICTA

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Quantitative Medicine

                            Deal Size : $1.8 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Predictive Oncology Completes Acquisition of Quantitative Medicine

                            Details : Integrating QM’s proven machine learning platform, CoRE, with Predictive Oncology's proprietary database of drug response and genomics profiles is expected to revolutionize the role of its AI-driven predictive models in the discovery and development of...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 07, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Quantitative Medicine

                            Deal Size : $1.8 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed

                            Predictive Oncology

                            U.S.A arrow
                            ECRM CMO & Packaging
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NSP-10 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Dr. Daniel Carter

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Predictive Oncology and Dr. Daniel Carter Collaborating to Develop a Potential COVID-19 Vaccine Using Novel Na...

                            Details : POAI has signed an agreement with Dr. Carter in which POAI licenses a ground-breaking vaccine technology developed by Dr. Carter based on an NSP-10 self-assembled nanoparticle.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 05, 2020

                            Lead Product(s) : NSP-10 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Dr. Daniel Carter

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth